ANVS phase III Alzheimer’s trial enrolled; top-line due March
ANVS says its phase III Alzheimer’s trial is fully enrolled, with top-line data expected in March and an NDA filing to follow. It also plans a $15 million raise before Q4 to fund needs.
The pivotal phase III Alzheimer’s trial is now fully enrolled, with top-line data due in March and an NDA filing to follow. The company said it needs a $15 million raise before Q4, with management and insiders participating. It is targeting disease-modifying data and commercialization for 2028, and said regulatory…